SCHEMBL1600077

SCHEMBL1600077

O=C(O)c1ccc(OCc2ccccc2)c(OCc2ccccc2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.62
HPGD P15428 3/20 0.62
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
RXRA P19793 4/20 0.62
NR4A2 P43354 2/20 0.62
NR4A1 P22736 1/20 0.62
NR4A3 Q92570 1/20 0.62
SMPD1 P17405 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
PTGER1 P34995 1/20 0.59
POLB P06746 1/20 0.59
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
RXRB P28702 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29556736 1.00 MRGPRX4 (0.62) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL10857748 0.98 MRGPRX4 (0.61) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL4280782 0.92 MRGPRX4 (0.74) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3944668 0.92 MRGPRX4 (0.59) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL242563 0.91 MRGPRX4 (0.77) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL29375753 0.91 SMPD1 (0.75) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL1029034 0.91 SMPD1 (0.75) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL7863787 0.90 MRGPRX4 (0.56) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL9197479 0.89 MEN1 (0.56) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL11271923 0.89 SMPD1 (0.73) MRGPRX4HPGDNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4678637-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS A-chembio Co., Ltd (KR) 2026-01-14 EP disclosed
US-20250120944-A1 ANTIBACTERIAL COMPOSITION SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-04-17 US disclosed
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES, INC. 2024-10-10 US disclosed
WO-2024186175-A1 NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS 주식회사 에이켐바이오 2024-09-12 WO disclosed
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS A-CHEMBIO CO., LTD (KR) 2024-09-12 US disclosed
EP-4410774-A1 ANTIBACTERIAL COMPOSITION Seoul National University R&DB Foundation (KR) 2024-08-07 EP disclosed
EP-4370113-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS Avanti Biosciences Inc. (US) 2024-05-22 EP disclosed
WO-2023048337-A1 ANTIBACTERIAL COMPOSITION 서울대학교산학협력단 2023-03-30 WO disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
WO-2023288020-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS AVANTI BIOSCIENCES INC. (US) 2023-01-19 WO disclosed
US-4501912-A AMINO-2-HYDROXYROPYLBENZOATE COMPOUND OR SALT WITH LONG DURATION IN OCULAR FLUID; RAPID METABOLISM AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1985-02-26 US disclosed
EP-0093765-A4 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES. AMERICAN HOSPITAL SUPPLY CORP (US) 1984-04-27 EP disclosed
EP-0081580-A4 COMPOSITIONS FOR TREATING GLAUCOMA. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-12-01 EP disclosed
EP-0093765-A1 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-11-16 EP disclosed
US-4402974-A WITH CARBOXY, OXY, CARBO-AMINE AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1983-09-06 US disclosed
EP-0081580-A1 COMPOSITIONS FOR TREATING GLAUCOMA. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-06-22 EP disclosed
WO-1983001770-A1 2-HYDROXYPROPYLAMINE ARYL ESTER DERIVATIVES AMERICAN HOSPITAL SUPPLY CORP (US) 1983-05-26 WO disclosed
WO-1983000043-A1 COMPOSITIONS FOR TREATING GLAUCOMA AMERICAN HOSPITAL SUPPLY CORP (US) 1983-01-06 WO disclosed
US-4239903-A ANTISPASMODIC AGENTS DAIICHI SEIYAKU CO., LTD. (JP) 1980-12-16 US disclosed
US-4118507-A Benzodioxincarboxamide lipogenesis inhibitors SHELL OIL COMPANY (US) 1978-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120944-A1 ANTIBACTERIAL COMPOSITION SQSTM1, BECN1, ATG7 MRGPRX4 2939/4885HPGD 3714/4885NPC1 553/4885
US-20240336588-A1 COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS MPO, GPX4, GPX1 MRGPRX4 3223/4885HPGD 147/4885NPC1 2007/4885
US-20240300913-A1 FLAVONE DERIVATIVE AND USE THEREOF FOR IMPROVING PULMONARY FIBROSIS HGF, FN1, SMAD2 MRGPRX4 3065/4885HPGD 2542/4885NPC1 4419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.